Alnylam Pharmaceuticals (AgeTech UK) Covid-19

Covid-relevant. Alnylam has led the translation of RNAi (RNA interference) from Nobel Prize-winning discovery into an innovative, entirely new class of medicines. Founded in 2002 by a team of distinguished scientific leaders, Alnylam’s vision is to harness the potential of RNAi therapeutics to transform the lives of people living with diseases for which there are limited or inadequate treatment options. Our pioneering work has delivered the world’s first and only approved RNAi therapeutics – ONPATTRO (patisiran) in 2018 and GIVLAARI® (givosiran) in 2019. We are advancing a deep pipeline of innovative RNAi-based medicines in four therapeutic areas: genetic medicines, cardio-metabolic diseases, infectious diseases, and central nervous system (CNS) and ocular diseases.

Investors

Connections from

Headquarters: United Kingdom
Funding Status: N/A
Employee Number: N/A
Investment Stage: N/A
Number Of Exists: N/A
Technology: AgeTech Companies
Investor Type: N/A
Founded Date: N/A
Industry: UK AgeTech 2020
N/A
Register and Claim Ownership